MNPR
Monopar Therapeutics Inc.
0.40
USD
This page is just a preview of the data found in TrendSpider’s full version
Monopar Therapeutics Inc. stock is up 8.11% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 4 December’s closed higher than November.
Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
